{"id":"ari-0001-cells","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cytokine release syndrome"},{"rate":"20-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL5852205","moleculeType":null,"molecularWeight":"373.82"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARI-0001 cells are a type of CAR-T cell therapy that involves genetically modifying a patient's T cells to recognize and attack cancer cells. This approach has shown promise in treating various types of blood cancers.","oneSentence":"ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:06.524Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell acute lymphoblastic leukemia"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07412405","phase":"NA","title":"This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R","status":"NOT_YET_RECRUITING","sponsor":"GUSTAVO SALGUERO","startDate":"2026-09-01","conditions":"Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)","enrollment":12},{"nctId":"NCT05641428","phase":"PHASE2","title":"Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2022-10-18","conditions":"NHL, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":300},{"nctId":"NCT04778579","phase":"PHASE2","title":"Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sara V. Latorre","startDate":"2021-05-11","conditions":"Acute Lymphoid Leukemia","enrollment":50},{"nctId":"NCT03144583","phase":"PHASE1","title":"Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy","status":"COMPLETED","sponsor":"Sara V. Latorre","startDate":"2017-06-15","conditions":"Leukemia, Lymphoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CART19","PEI 19-187"],"phase":"phase_2","status":"active","brandName":"ARI-0001 cells","genericName":"ARI-0001 cells","companyName":"Sara V. Latorre","companyId":"sara-v-latorre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARI-0001 cells are a type of immunotherapy that stimulate the immune system to attack cancer cells. Used for Relapsed or refractory B-cell acute lymphoblastic leukemia, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}